About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

NCT00943501·20 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novo Nordisk A/S

Age

10–17

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

BMI greater than 85th percentile for age and gender
Currently being treated with diet and exercise or metformin alone
HbA1c (glycosylated haemoglobin) between 6.5 and 11.0%

You may not be if

Any clinically significant disease other than type 2 diabetes, as judged by the trial physician
Previous treatment with any anti-diabetic drug other than metformin (except for prior short term treatment, at the discretion of the trial physician)

The record

StatusCompleted

PhasePhase 1

Taking part21

StartedNov 2009

UpdatedJan 26, 2017

Conditions

Diabetes Diabetes Mellitus, Type 2

Where20

Novo Nordisk Investigational Site
Cypress, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States

Clareo Health | Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes